「with t」の検索結果
81件：31～35件目を表示
-
ry Eye Disease (DED), has been launched in Japan today. Avarept® represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1) *1 antagonist, designe...
https://www.senju.co.jp/system/files/content_news/2026-04/ENG_20260406_0.pdf -
Research and Development System | Research & Development | SENJU Pharmaceutica
l R&D initiatives but also to R&D projects involving global joint studies and collaboration with industry, government, and academia by leveraging flexible ideas and thinking beyond conventiona...
http://www.senju.co.jp/english/rd/about/ -
pan as of December 22, 2025. Avarept® Ophthalmic suspension 0.3% represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1)*1 antagonist, designed...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222_0.pdf -
Mytear Fresh40 | OTC Products, etc. | Products | SENJU Pharmaceutical
Category 3 OTC medicines Mytear® Fresh40 For blurred vision and eyestrain CHARACTERISTICS With the effects of improved focus adjustment by neostigmine methylsulfate, oxygen uptake into the eyes by pot...
http://www.senju.co.jp/english/products/mytearfresh.html -
Compliance System | Our Initiatives for Society/Environment | About Senju | SENJU Pharmaceutical
oyees and other members of Senju Pharmaceutical Co., Ltd. (“SENJU”) will act in compliance not only with the law but will operate under a high standard of ethical values so as to conduct business mana...
https://www.senju.co.jp/english/about/csr03.html